PDSB (PDS Biotechnology) Float Percentage Of Total Shares Outstanding : 96.71% (As of Dec. 12, 2024)

View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PDS Biotechnology's float shares is 36.18 Mil. PDS Biotechnology's total shares outstanding is 37.41 Mil. PDS Biotechnology's float percentage of total shares outstanding is 96.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PDS Biotechnology's Insider Ownership is 7.99%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PDS Biotechnology's Institutional Ownership is 13.08%.

PDS Biotechnology Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

PDS Biotechnology's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	36.18	/	37.41
	=	96.71%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

EU6:Germany

Address

303A College Road, East Princeton, NJ, USA, 08540

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Executives

Spencer D. Brown	officer: Senior VP, General Counsel	25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill	officer: Chief Financial Officer	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist	director, 10 percent owner	RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King	officer: Interim Chief Financial Office	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev	director	303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk	officer: Principal Accounting Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes	director	C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo	director, 10 percent owner, officer: President/CEO	300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood	officer: Chief Medical Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn	officer: Chief Scientific Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922